TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Brief Summary: The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
B: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
C: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Brief Summary: The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.


Options:
A: Arm Label: low molecular weight heparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin Sodium | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin Sodium; Assigned to Arm(s): low molecular weight heparin
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
C: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
D: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Brief Summary: The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.


Options:
A: Arm Label: Group A(heparin group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Group A(heparin group)
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
Brief Summary: The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.


Options:
A: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
B: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
D: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Continuous Glucose Monitoring With and Without Real Time Access to Glucose Values and Glucose Alerts on Course of Glucose and Satisfaction With CGMS in Type 1 Diabetic Patients
Brief Summary: The objective of this cross over study is to access if continuous glucose monitoring (CGMS) with a real time feed back and hypoglycemic as well as hyperglycemic glucose alerts vs. only retrospective analysis of glucose values is able to improve course of glucose with special regard to time spent in hypoglycemic glucose ranges in type 1 diabetic patients with impaired hypoglycemia awareness or a history of severe hypoglycemia. The second objective is to access satisfaction with CGMS during both conditions


Options:
A: Arm Label: Conventional insulin pump therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Minimed Paradigm 512/712 Insulin pump | Arm Label: Minimed paradigm Real Time Sytem; Type: EXPERIMENTAL; Interventions: Device: Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed paradigm Real Time Sytem; Assigned to Arm(s): Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed Paradigm 512/712 Insulin pump; Assigned to Arm(s): Conventional insulin pump therapy
B: Arm Label: Open; Type: EXPERIMENTAL; Interventions: Device: Real-Time Continuous Glucose monitoring System (RT-CGMS) | Arm Label: Blind; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Real-Time Continuous Glucose monitoring System (RT-CGMS); Assigned to Arm(s): Open
C: Arm Label: A,1; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Arm Label: A,2; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Intervention Type: DEVICE; Name: Real time access to current glucose values during CGMS; Assigned to Arm(s): A,1, A,2
D: Arm Label: 722 sensor augmented pump; Type: EXPERIMENTAL; Interventions: Device: MiniMed Paradigm REAL-Time System | Arm Label: Multiple Daily Injections (MDI); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MiniMed Paradigm REAL-Time System; Assigned to Arm(s): 722 sensor augmented pump

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Fortified Products on Improving Long Term Cognitive Performance in School Children in India
Brief Summary: Nutritional deficiencies are a major problem in school children in India and have a variety of adverse effects on their cognitive development and growth, and increase susceptibility to infections. There is strong evidence for beneficial effects of iodine, iron and protein-energy on cognitive development in children, while evidence for vitamin B6, vitamin B12, folate, zinc and, omega-3 fatty acids and in particular docosahexanoic acid (DHA) is limited and inconclusive. A randomised, double-blind, placebo-controlled 2x2 factorial design will be conducted to assess the effect of a micronutrient with or without omega-3 fatty acids on cognitive development and performance and other selected outcome variables such as growth, morbidity and immune response in children of 7-9 years of age in India.


Options:
A: Arm Label: Hgh micronutrients, high n-3 fatty acid treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: low micronutrients, high n-3 fatty acid treatment; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: low micronutrients, low n-3 fatty acid treatment.; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Arm Label: high micronutrients, low n-3 fatty acid treatment; Type: EXPERIMENTAL; Interventions: Behavioral: micronutrients | Intervention Type: BEHAVIORAL; Name: micronutrients; Assigned to Arm(s): Hgh micronutrients, high n-3 fatty acid treatment Arm, high micronutrients, low n-3 fatty acid treatment, low micronutrients, high n-3 fatty acid treatment, low micronutrients, low n-3 fatty acid treatment.
B: Arm Label: no school meal; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: normal school meal; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: cold extruded fortified rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fortified rice cold extruded kernel | Arm Label: warm extrusion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortified rice warm extruded kernel | Arm Label: hot extruded; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortiified rice hot extruded kernel | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified rice cold extruded kernel; Assigned to Arm(s): cold extruded fortified rice | Intervention Type: DIETARY_SUPPLEMENT; Name: fortified rice warm extruded kernel; Assigned to Arm(s): warm extrusion | Intervention Type: DIETARY_SUPPLEMENT; Name: fortiified rice hot extruded kernel; Assigned to Arm(s): hot extruded
C: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
D: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Brief Summary: Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.

(2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity.

The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.


Options:
A: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: risperidone plus parent management training; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Behavioral: Behavior Therapy | Arm Label: risperidone only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone only, risperidone plus parent management training | Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): risperidone plus parent management training
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Brief Summary: Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.

(2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity.

The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Brief Summary: Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.

(2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity.

The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.


Options:
A: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
C: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo
D: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
Brief Summary: The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.


Options:
A: Arm Label: SPD489; Type: EXPERIMENTAL; Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD489 (Lisdexamfetamine dimesylate); Assigned to Arm(s): SPD489 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A
C: Arm Label: Adderall Extended Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Arm Label: Adderall Immediate Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Intervention Type: DRUG; Name: Adderall ® Immediate Release; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First | Intervention Type: DRUG; Name: Adderall XR ®; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First
D: Arm Label: SPD489; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPD489 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SPD489; Assigned to Arm(s): SPD489 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies
Brief Summary: This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
B: Arm Label: MabThera/Rituxan; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): MabThera/Rituxan | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): MabThera/Rituxan
C: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Trial of Transcervical Foley Catheter With or Without Oxytocin for Preinduction Cervical Ripening
Brief Summary: The transcervical Foley catheter (TFC) is a proven and effective mode of cervical ripening. It is common practice to use TFC with simultaneous low-dose oxytocin under the assumption that the combination results in a more successful labor induction. Scientific validation of this practice is lacking. We seek to determine if the addition of oxytocin to TFC improves induction success.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS Foley and oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS no Foley bulb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin, PROMS Foley and oxytocin
B: Intervention Type: DRUG; Name: low dose oxytocin; Assigned to Arm(s): N/A
C: Arm Label: Nulliparous - Foley only; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcervical Foley catheter | Arm Label: Nulliparous - Foley and oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin, Device: Transcervical Foley catheter | Arm Label: Multi(primi)parous - Foley only; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcervical Foley catheter | Arm Label: Multi(primi)parous - Foley and oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin, Device: Transcervical Foley catheter | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Multi(primi)parous - Foley and oxytocin, Nulliparous - Foley and oxytocin | Intervention Type: DEVICE; Name: Transcervical Foley catheter; Assigned to Arm(s): Multi(primi)parous - Foley and oxytocin, Multi(primi)parous - Foley only, Nulliparous - Foley and oxytocin, Nulliparous - Foley only
D: Intervention Type: DEVICE; Name: Transcervical Foley Catheter; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Transcervical Foley Catheter with an EASI; Assigned to Arm(s): N/A

Answer: B